Immunovant Inc

IMVT is in a Stage 2 advancing regime within a persistent long-term uptrend. After the mid-July Bullish Exhaustion signal, price has pulled back into the rising 9- and 21-EMA zone and is holding dynamic support, presenting a buy-the-dip opportunity for continuation participation under the Momentum + EPS strategy.

• ↑Stock hit a 52-week high of $36.39, up 128% YoY on positive trial data.
• ↑Phase 2a IMVT-1402 showed efficacy in rheumatoid arthritis; Phase 2b CIDP trial underway.
• ↓Net loss widened to $0.73 /sh in Q4 2026; FY26 loss $2.77 /sh, exceeding estimates.